Neoadjuvant immunotherapy was preferably recommended to treat T3/T4 colorectal cancer with dMMR/ MSI-h in the National Comprehensive Cancer Network (NCCN) guidelines version 2.2023 [20, 21], whereas no recommendation were made on the use of anti-PD-1/PDL1 inhibitors in the European Society for Medical Oncology (ESMO) guidelines [22]. The gene discussed is PDCD1; the disease is colorectal cancer.